A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma. (NCT04680052)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to Rituximab Versus Lenalidomide in Addition to Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma Grade 1 to 3a or R/R Marginal Zone Lymphoma
🩺 Plain-English Summary (8th-Grade Level)
This is a Phase 3 double-blind, placebo-controlled, randomized study designed to investigate whether tafasitamab and lenalidomide as an add-on to rituximab provides improved clinical benefit compared with lenalidomide as an add-on to rituximab in patients with R/R FL Grade 1 to 3a or R/R MZL.
Who can join: Review the eligibility criteria below.
Location: John Muir Health Clinical Research Center — Concord, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (261 Sites)
Showing the first 25 of 261 sites.
- John Muir Health Clinical Research Center — Concord, California
- Marin Cancer Care — Greenbrae, California
- The Oncology Institute of Hope and Innovation — Pasadena, California
- Sharp Memorial Hospital — San Diego, California
- Middlesex Hospital Cancer Center — Middletown, Connecticut
- Smilow Cancer Hospital — New Haven, Connecticut
- Cancer Specialists of North Florida — Jacksonville, Florida
- Brcr Medical Center, Inc — Plantation, Florida
- Asclepes Research Centers — Weeki Wachee, Florida
- Northwest Georgia Oncology Centers,P.C — Marietta, Georgia
- Straub Medical Center — Honolulu, Hawaii
- Des Moines Oncology Research Association — Des Moines, Iowa
- Baptist Health Lexington — Lexington, Kentucky
- Norton Cancer Institute — Louisville, Kentucky
- Tulane University — New Orleans, Louisiana
- University of Maryland-Greenebaum Cancer Center — Baltimore, Maryland
- Cancer Center For Blood Disorders — Bethesda, Maryland
- Barbara Ann Karmanos Cancer Hospital — Detroit, Michigan
- Metro-Minnesota Community Oncology Reserch Consortium (Mmcorc) — Saint Louis Park, Minnesota
- Hattiesburg Clinic Hematology — Hattiesburg, Mississippi
- Roswell Park Cancer Institute — Buffalo, New York
- Nyu Clinical Cancer Center — New York, New York
- Levine Cancer Institute — Charlotte, North Carolina
- Integris Cancer Institute — Oklahoma City, Oklahoma
- Charleston Hematology Oncology Associates — Charleston, South Carolina
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Follicular Lymphoma
- A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas — New York, New York
- Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma — Bethesda, Maryland
- Measuring Cell-Free DNA (cfDNA) Levels in People With Follicular Lymphoma — Basking Ridge, New Jersey
- Tazemetostat and Mosunetuzumab in Untreated Follicular Lymphoma — New York, New York
- Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma — Boston, Massachusetts
Explore by condition: All Follicular Lymphoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.